Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, doing business as Cleveland Clinic LOU Ruvo Center, is a non-profit academic medical institution and federal grant recipient conducting peer-reviewed biomedical research and clinical training across multiple National Institutes of Health (NIH) institutes and centers. The organization acts exclusively as a grant recipient on federal research awards; it holds no federal contracts and does not operate as a contractor or subcontractor to other prime contractors.

The institution's federal footprint centers on NIH-funded basic, translational, and clinical research. Cleveland Clinic Lerner College operates as a prime recipient on 1,126 federal grants and serves as a sub-recipient on 258 grants, predominantly from NIH components. The top five funding agencies by award count are the NIH (393 awards overall), the National Heart Lung and Blood Institute (191 awards, $21.7 million combined potential value), the National Cancer Institute (135 awards), the National Institute of Diabetes and Digestive and Kidney Diseases (110 awards), and the National Institute of Neurological Disorders and Stroke (97 awards). Combined potential value across all recent awards totals $26.1 million, though obligated dollars across all awards reach $2.72 billion, reflecting the long duration and cumulative value of multi-year research grants, particularly R01s and project grants.

Recent grant work demonstrates a broad research portfolio spanning oncology, neurodegenerative disease, immunology, and metabolic disease. Representative examples include a $1.964 million National Cancer Institute award (September 2025) investigating VISTA's role in driving immune evasion in acute myeloid leukemia; a $2.65 million National Institute on Aging award (September 2025) examining neural mechanisms underlying aerobic exercise benefits in advanced Parkinson's disease; a $1.479 million National Institute of Diabetes and Digestive and Kidney Diseases award (June 2026) on hepatocyte nuclear receptor 4 alpha as a mediator of environmental risk in inflammatory bowel disease; and a $640.775 million National Cancer Institute award (June 2026) on co-clinical trials of intratumoral bacteria's role in head and neck squamous cell carcinoma immunosuppression. The institution also holds sub-recipient positions on collaborative research networks including the Dementia with Lewy Bodies Consortium, the NEPTUNE kidney disease study, and multiple NCI-funded cancer consortia, reflecting its role as a regional research center participating in multi-site clinical and translational studies.

Activity has grown year over year from 82 awards in 2023 to 122 in 2024 and 123 in 2025, with 152 grants reaching ultimate completion within the next twenty-four months and thus facing recompete or continuation decisions in that window. The institution functions as an independent research recipient and does not engage in federal contracting, teaming with other contractors, or sub-award performance under commercial prime contractors. Performance occurs in Cleveland, Ohio, with administrative oversight at the Cleveland Clinic's main campus at 9500 Euclid Avenue.